AnaptysBio
ANAB
135 hedge funds and large institutions have $469M invested in AnaptysBio in 2024 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 50 increasing their positions, 35 reducing their positions, and 52 closing their positions.
43% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 35
5.04% more ownership
Funds ownership: 111.35% → 116.39% (+5%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
16% less funds holding
Funds holding: 160 → 135 (-25)
39% less call options, than puts
Call options by funds: $21M | Put options by funds: $34.3M
48% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 52
58% less capital invested
Capital invested by funds: $1.13B → $469M (-$658M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
+$44M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$30.3M |
| 3 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$10M |
| 4 |
State Street
Boston,
Massachusetts
|
+$9.19M |
| 5 |
BlackRock
New York
|
+$8.92M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$23.1M |
| 2 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$15.4M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$11.5M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$10.2M |
| 5 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$8.84M |
ANAB Hedge Fund Activity: Q4 2024 in Review
135 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in AnaptysBio (ANAB) for Q4 2024, worth a combined $469M — down 58% from $1.13B a quarter earlier.
Sellers outnumbered buyers: 52 funds closed out of ANAB and 27 opened new positions — a net loss of 25 holders — while 35 trimmed existing stakes and 50 added.
The largest buyer was Fairmount Funds Management, opening a new position worth an estimated $44M. The largest seller was Mangrove Partners, exiting entirely with an estimated $23.1M sold.
- 135 institutional investors held AnaptysBio (ANAB) as of Q4 2024, down from 160 in Q3 2024.
- Funds reported $469M of AnaptysBio stock for Q4 2024, down 58% quarter-over-quarter.
- 27 funds opened new AnaptysBio positions in Q4 2024 and 52 closed out, a net change of -25 holders.
- The largest AnaptysBio buyer in Q4 2024 was Fairmount Funds Management, an estimated $44M added.
- The largest AnaptysBio seller in Q4 2024 was Mangrove Partners, an estimated $23.1M sold.
Based on aggregated 13F filings for Q4 2024.